Shishihakuhito, a Kampo medicine for atopic dermatitis, suppresses NGF-induced neurite extension by inhibition of MEK/ERK signaling in PC12D cells

DOI Web Site
  • Nakanishi Koichiro
    Department of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Kawahata Ichiro
    Department of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Sun Wen
    Department of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Wang Yu
    Department of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Tohoku University
  • Yoshida Masaaki
    Research Laboratory, Kotaro Pharmaceutical Co., Ltd
  • Ohizumi Yasushi
    Yokohama College of Pharmacy Research Center of Supercritical Fluid Technology, Graduate School of Engineering, Tohoku University Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka
  • Yamakuni Tohru
    Department of Pharmacotherapy, Graduate School of Pharmaceutical Sciences, Tohoku University

Search this article

Description

Accumulating evidence obtained from clinical studies as well as animal studies suggests that nerve growth factor (NGF) may play a crucial role in the pathogenic mechanism of atopic dermatitis (AD), involving severe scratching due to itching. Shishihakuhito is a Kampo medicine for AD. In the current study, we for the first time report that shishihakuhito extract has the activity to prevent NGF-induced stimulation of phoshorylation of MEK and ERK which has been demonstrated to mediate neurite outgrowth induced by this neurotrophic factor, and actually inhibit NGF-induced neurite extension in PC12D cells, a cellular model of peripheral sensory neurons. These findings suggest that shishihakuhito might prevent NGF signaling, thereby reducing the induction of severe itching and scratching in AD.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top